Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AGEN

Agenus Inc

Mar 14 • 04:00PM ET

1.86

Dollar change +0.19
Percentage change 11.04	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD JNJ AMGN VRTX REGN BIIB LLY

| Held by: VTI VXF IWM VTWO IWN VHT IWO IWC CNCR VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-10.69	Insider Own	2.44%	Shs Outstand	23.46M	Perf Week	-20.85%
Market Cap	43.63M	Forward P/E	-	EPS next Y	-2.65	Insider Trans	0.00%	Shs Float	22.89M	Perf Month	-46.24%
Income	-228.32M	PEG	-	EPS next Q	-1.75	Inst Own	35.14%	Short Float	14.09%	Perf Quarter	-44.56%
Sales	103.46M	P/S	0.42	EPS this Y	51.84%	Inst Trans	-4.28%	Short Ratio	7.65	Perf Half Y	-67.02%
Book/sh	-13.48	P/B	-	EPS next Y	47.97%	ROA	-79.32%	Short Interest	3.23M	Perf Year	-86.10%
Cash/sh	1.72	P/C	1.08	EPS next 5Y	43.40%	ROE	-	52W Range	1.67 - 19.69	Perf YTD	-32.12%
Dividend Est.	-	P/FCF	-	EPS past 5Y	7.90%	ROI	-	52W High	-90.55%	Beta	1.56
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	33.20%	Gross Margin	139.68%	52W Low	11.38%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	23.02%	Oper. Margin	-97.43%	RSI (14)	25.98	Volatility	15.05% 9.27%
Employees	389	Debt/Eq	-	Sales Y/Y TTM	-33.81%	Profit Margin	-220.68%	Recom	2.50	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	13.20%	Payout	-	Rel Volume	2.23	Prev Close	1.67
Sales Surprise	-11.35%	EPS Surprise	19.75%	Sales Q/Q	-67.98%	Earnings	Mar 11 BMO	Avg Volume	421.33K	Price	1.86
SMA20	-31.37%	SMA50	-40.86%	SMA200	-69.75%	Trades		Volume	939,829	Change	11.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-24	Downgrade	Robert W. Baird	Outperform → Neutral	$35 → $8
Jul-18-24	Downgrade	William Blair	Outperform → Mkt Perform
Jul-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$9
Jun-06-23	Initiated	Robert W. Baird	Outperform	$8
Jun-06-23	Initiated	Robert W. Baird	Outperform	$60 → $80
Feb-28-23	Resumed	H.C. Wainwright	Buy	$8
Sep-28-22	Initiated	SMBC Nikko	Outperform	$5
Dec-16-21	Initiated	H.C. Wainwright	Buy	$12
Nov-19-19	Resumed	B. Riley FBR	Buy	$6
Apr-22-19	Initiated	B. Riley FBR	Buy
Oct-28-16	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $5
Oct-27-16	Reiterated	Maxim Group	Buy
Mar-11-16	Upgrade	Maxim Group	Hold → Buy	$7
Dec-16-15	Initiated	Jefferies	Buy
Oct-27-15	Downgrade	Maxim Group	Buy → Hold
Jul-27-15	Reiterated	MLV & Co	Buy	$9 → $11
Jun-11-15	Initiated	Oppenheimer	Outperform	$14
Jan-12-15	Reiterated	Maxim Group	Buy	$10 → $11
Jan-09-15	Reiterated	MLV & Co	Buy	$6 → $9
Jan-09-15	Reiterated	Maxim Group	Buy	$10 → $11

Show Previous Ratings

Mar-12-25 03:03AM	Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges (GuruFocus.com) -9.02%
01:35AM	Q4 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 11:45AM	Agenus (AGEN) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:43AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Loading…
07:30AM	Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program (Business Wire)
Feb-26-25 04:48PM	Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications (Business Wire) -8.63%
Feb-25-25 02:30PM	Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference (Business Wire)
08:26AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (Business Wire)
Feb-24-25 08:33AM	Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting (Business Wire)
Feb-23-25 07:38PM	CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting (Business Wire)
Feb-21-25 09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-12-25 01:00PM	Agenus BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting (Business Wire) +7.79%
Feb-06-25 08:50AM	Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-05-25 09:40AM	Are Medical Stocks Lagging Agenus (AGEN) This Year? (Zacks) +11.43%
12:37PM	Loading…
Jan-29-25 12:37PM	Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas (Business Wire)
Jan-22-25 02:48PM	Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease (Business Wire)
Jan-20-25 12:00PM	What Makes Agenus (AGEN) a New Buy Stock (Zacks)
09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-18-24 07:30AM	Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers (Business Wire) -8.12%
Dec-06-24 06:07AM	AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B (BioPharma Dive) +14.01%
Dec-05-24 07:30AM	Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs (Business Wire) -8.45%
Nov-27-24 10:20AM	Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development (Benzinga)
08:15AM	Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment (Business Wire)
Nov-19-24 09:35AM	Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 09:35AM	Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-15-24 09:35AM	Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround (Zacks)
Nov-13-24 02:18AM	Q3 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... (GuruFocus.com)
Nov-12-24 12:15PM	Agenus (AGEN) Q3 2024 Earnings Call Transcript (Motley Fool) -20.38%
08:20AM	Loading…
08:20AM	Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development (Business Wire)
Nov-11-24 07:24AM	Earnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 Result (GuruFocus.com)
Nov-07-24 10:00AM	Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 (Business Wire) -6.87%
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-05-24 07:30AM	Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update (Business Wire)
Nov-01-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Oct-29-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-19-24 01:31PM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-17-24 05:45AM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-16-24 12:51PM	Agenus Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-13-24 10:00AM	Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 (Business Wire) +5.56%
Sep-09-24 07:30AM	Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 (Business Wire)
Sep-03-24 07:30AM	Agenus to Participate in September Investor Conferences (Business Wire)
Aug-08-24 04:15PM	Agenus (AGEN) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:08AM	Agenus: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Second Quarter 2024 Operational and Financial Results (Business Wire)
07:00AM	Agenus Announces Appointment of Tom Harrison to Board of Directors (Business Wire)
Aug-07-24 10:58AM	Agenus Publishes Seminal Study on Botensilimabs Activity in Treatment-Resistant Cancers (Business Wire) -6.45%
Aug-05-24 02:31PM	Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus (Benzinga) -6.93%
07:23AM	Bristol Myers sends TIGIT drug back to Agenus (BioPharma Dive)
Aug-01-24 10:01AM	Agenus (AGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-26-24 07:00AM	Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update (Business Wire) +9.97%
Jul-19-24 10:39AM	Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data (Zacks) -17.95%
07:47AM	Lilly alone in bidding for Morphic; Novartis wont yet file MorphoSys drug (BioPharma Dive)
Jul-18-24 07:00AM	Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer (Business Wire) -58.83%
Jun-28-24 11:10AM	Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference (Business Wire) +18.63%
Jun-27-24 07:30AM	Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies (Business Wire)
Jun-17-24 07:00AM	Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors (Business Wire) -7.50%
Jun-13-24 05:15AM	Nature Medicine Reports Agenus Novel Immunotherapy Demonstrates Clinical Activity Against a Deadly Form of Colorectal Cancer on the Rise in Americans Under 50 (Business Wire) -5.44%
Jun-04-24 07:30AM	Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
May-30-24 03:30PM	Medical Moonshots: 3 Biotech Stocks Set to Skyrocket (InvestorPlace)
May-27-24 12:32PM	7 Biotech Stocks to Put on Your Breakthrough Radar (InvestorPlace)
May-24-24 05:00PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +10.28% +11.97%
May-23-24 05:10PM	Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting (Business Wire)
07:30AM	Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-22-24 07:30AM	3 Magnificent Growth Stocks to Buy Hand Over Fist (Motley Fool) +7.10%
May-16-24 07:30AM	FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer (Business Wire)
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:11AM	Agenus Inc. (NASDAQ:AGEN) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:09AM	Agenus Inc (AGEN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-07-24 05:45PM	Agenus (AGEN) Q1 2024 Earnings Call Transcript (Motley Fool) -7.26%
01:52PM	Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading (MT Newswires)
12:24PM	Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates (MT Newswires)
09:00AM	Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
08:56AM	Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments (GuruFocus.com)
07:59AM	Agenus: Q1 Earnings Snapshot (Associated Press Finance)
07:40AM	Agenus Reports First Quarter 2024 Results (Business Wire)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
May-01-24 07:30AM	Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement (Business Wire) +9.41%
Apr-28-24 08:30AM	Up 40%: Is This Red-Hot Growth Stock Still a Buy? (Motley Fool)
Apr-24-24 10:00AM	Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting (Business Wire) +14.86%
Apr-23-24 07:30AM	Agenus to Provide First Quarter 2024 Financial Report and Corporate Update (Business Wire) +11.96%
Apr-22-24 04:17AM	Agenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock? (Zacks) +8.66%
Apr-12-24 07:30AM	Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer (Business Wire) -8.12%
Apr-08-24 03:34AM	Down 75%. Is Agenus Stock a Buy on the Dip? (Motley Fool) -7.58%
Apr-05-24 04:30PM	Agenus Announces Reverse Stock Split of Common Stock (Business Wire)
Apr-03-24 04:19AM	2 Stocks That Could More Than Double Your Money, According to Wall Street: Are They Buys Now? (Motley Fool)
Mar-24-24 04:05PM	3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million (InvestorPlace)
Mar-22-24 01:25PM	MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-15-24 02:11PM	Agenus Inc. (NASDAQ:AGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -9.95%
Mar-14-24 01:30PM	Agenus (AGEN) Q4 2023 Earnings Call Transcript (Motley Fool) -8.94%
08:51AM	Agenus Inc (AGEN) Reports Full Year and Q4 2023 Financial Results, Advances in Oncology Pipeline (GuruFocus.com)
07:39AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Fourth Quarter and Full Year 2023 Results (Business Wire)
Mar-06-24 07:30AM	Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 (Business Wire)
Mar-05-24 04:30PM	Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 07:30AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report (Business Wire) -10.81%

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGEN

Agenus Inc

Upgrade your FINVIZ experience